Frontotemporal dementia treatment: an umbrella review of meta-analyses of randomized controlled trials

Frontotemporal dementia (FTD) has no approved disease-modifying therapies, and the role and the evidence of symptomatic treatment are still debated. We conducted an umbrella review of meta-analyses of randomized controlled trials (RCTs) to summarise treatment efficacy. Three databases were searched from inception to 1 November 2025. We included systematic reviews with meta-analyses of randomised controlled trials (RCTs) in people with FTD, comparing any active intervention with placebo, sham, no treatment or an active control, published in English. Eligible outcomes were any clinical outcome, including behavioural and psychological symptoms of dementia, cognitive and language function, caregiver burden and activities of daily living; in practice, the outcomes reported by the included meta-analyses were predominantly cognitive and language tests. Network meta-analyses were excluded a priori. Two reviewers screened the literature and extracted data. Overlap of primary RCTs across the included reviews was quantified using the corrected covered area (CCA). Methodological quality was assessed with AMSTAR 2 and certainty of evidence with GRADE. Of 879 records identified, 558 were screened after removal of duplicates and 29 were assessed in full text; five meta-analyses were included, covering 22 unique RCTs and 15 outcomes. The outcomes were mainly cognitive and language tests. Meta-analysis quality was high in four and moderate in one. High-certainty evidence indicated that memantine, the only pharmacological treatment for which a meta-analysis of FTD-specific RCTs was available, was not superior to placebo for Global Clinical Impression, MMSE and Neuropsychiatric Inventory scores, or caregiver burden. In PPA, non-invasive brain stimulation (NIBS) considered overall showed no benefit for naming (SMD 0.06, 95% CI − 0.05 to 0.17) and a very modest improvement in phonemic fluency (SMD 0.11, 95% CI 0.02 to 0.21), both with very low certainty. In tDCS-specific analyses, tDCS improved trained naming (SMD 0.67, 95% CI 0.23 to 1.11; low certainty) and untrained naming (SMD 0.31, 95% CI 0.15 to 0.47; moderate certainty), with no consistent effects on other outcomes. Meta-analytic evidence for the symptomatic treatment of FTD is scarce and concentrated on a small number of interventions and outcomes. High-certainty evidence did not support a benefit of memantine over placebo for the evaluated outcomes. Small trials suggested a possible benefit of tDCS on naming in PPA; this signal warrants further investigation as an adjunctive intervention rather than clinical adoption. Larger phenotype-stratified trials with patient- and caregiver-relevant endpoints are needed.

Authors

Institutions

Publication Details

Journal
Aging Clinical and Experimental Research
Published
2026-11-19
DOI
https://doi.org/10.1007/s40520-026-03563-5
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Frontotemporal dementia treatment: an umbrella review of meta-analyses of randomized controlled trials

Francesca Burgio, Andrea Pilotto, Nicola Veronese, Diego De Leo et al.
Aging Clinical and Experimental Research
Dementia and Cognitive Impairment Research
article

Frontotemporal dementia treatment: an umbrella review of meta-analyses of randomized controlled trials

Francesca Burgio, Andrea Pilotto, Nicola Veronese, Diego De Leo, Livia Gallo, Pınar Soysal, Luisa Solimando, Ilenia Libri, Roberto Monastero, Alessandro Padovani, Francesco Bolzetta, Giorgia Durante, Marco Solmi, Lee Smith, Annalisa Tessari, Vitalba Bivona
article en

Abstract

Frontotemporal dementia (FTD) has no approved disease-modifying therapies, and the role and the evidence of symptomatic treatment are still debated. We conducted an umbrella review of meta-analyses of randomized controlled trials (RCTs) to summarise treatment efficacy. Three databases were searched from inception to 1 November 2025. We included systematic reviews with meta-analyses of randomised controlled trials (RCTs) in people with FTD, comparing any active intervention with placebo, sham, no treatment or an active control, published in English. Eligible outcomes were any clinical outcome, including behavioural and psychological symptoms of dementia, cognitive and language function, caregiver burden and activities of daily living; in practice, the outcomes reported by the included meta-analyses were predominantly cognitive and language tests. Network meta-analyses were excluded a priori. Two reviewers screened the literature and extracted data. Overlap of primary RCTs across the included reviews was quantified using the corrected covered area (CCA). Methodological quality was assessed with AMSTAR 2 and certainty of evidence with GRADE. Of 879 records identified, 558 were screened after removal of duplicates and 29 were assessed in full text; five meta-analyses were included, covering 22 unique RCTs and 15 outcomes. The outcomes were mainly cognitive and language tests. Meta-analysis quality was high in four and moderate in one. High-certainty evidence indicated that memantine, the only pharmacological treatment for which a meta-analysis of FTD-specific RCTs was available, was not superior to placebo for Global Clinical Impression, MMSE and Neuropsychiatric Inventory scores, or caregiver burden. In PPA, non-invasive brain stimulation (NIBS) considered overall showed no benefit for naming (SMD 0.06, 95% CI − 0.05 to 0.17) and a very modest improvement in phonemic fluency (SMD 0.11, 95% CI 0.02 to 0.21), both with very low certainty. In tDCS-specific analyses, tDCS improved trained naming (SMD 0.67, 95% CI 0.23 to 1.11; low certainty) and untrained naming (SMD 0.31, 95% CI 0.15 to 0.47; moderate certainty), with no consistent effects on other outcomes. Meta-analytic evidence for the symptomatic treatment of FTD is scarce and concentrated on a small number of interventions and outcomes. High-certainty evidence did not support a benefit of memantine over placebo for the evaluated outcomes. Small trials suggested a possible benefit of tDCS on naming in PPA; this signal warrants further investigation as an adjunctive intervention rather than clinical adoption. Larger phenotype-stratified trials with patient- and caregiver-relevant endpoints are needed.

Aging Clinical and Experimental Research
Griffith University (AU), University of Primorska (SI), University of Ottawa (CA), Ottawa Hospital (CA), Karolinska Institutet (SE), Bezmiâlem Vakıf Üniversitesi (TR), Saint Camillus International University of Health and Medical Sciences (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Biruni University (TR), IRCCS San Camillo Hospital (IT), Ospedale di Mirano (IT), Anglia Ruskin University (GB), Charité - Universitätsmedizin Berlin (DE), University of Brescia (IT), University of Palermo (IT)
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon